Hypothesis-Generating Brief: Omega 3 longevity

Hypothesis-Generating Brief: Omega 3 longevity

Abstract

Evidence-honesty note: 24/48 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 39/48 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Omega 3 longevity across 48 accepted source papers and 2985 high-confidence extracted claims.

The evidence profile contains 9 direct clinical sources, 38 adjacent clinical sources, and 1 mechanistic or model-system source, with 389 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the contextual adjacent evidence, longevity, safety and comorbidity outcome classes, null signals in the contextual adjacent evidence, muscle function and cardiometabolic outcome classes, and negative signals in the immune and inflammation outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Omega 3 longevity remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

This synthesis evaluates evidence on Omega 3 longevity across 48 included source papers and 2985 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 9 direct clinical sources, 38 adjacent clinical sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 48 curated reference papers, the evidence base for omega 3 longevity shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: immune. Null findings dominate: contextual other, muscle function. The synthesis surfaces 389 cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The omega 3 longevity anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

Background

The background evidence for Omega 3 longevity is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Amini 2026, Tobias 2025, Konert 2026 are interpreted separately from mechanistic studies such as Schlogelhofer 2025, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the contextual adjacent evidence, longevity, safety and comorbidity outcome classes; null signals around the contextual adjacent evidence, muscle function and cardiometabolic outcome classes; and negative or adverse signals around the immune and inflammation outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-omega_3_longevity-v06-DAILY-2026-06-23T19-44-33Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-23.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• omega 3 longevity AND aging AND human
• omega 3 longevity AND older adults
• omega 3 longevity AND randomized controlled trial
• omega-3 AND aging AND human
• omega-3 AND older adults
• omega-3 AND randomized controlled trial
• EPA AND aging AND human
• EPA AND older adults
• EPA AND randomized controlled trial
• DHA AND aging AND human

Eligibility criteria

• Sources whose primary content addresses omega 3 longevity.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 183 records in the receipt-candidate union, 63 were classified as source candidates and 48 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	183
Classified source candidates	63
No extractable claims	12
None-only claim binding	6
Mixed partial-or-none claim-binding candidates	50
Partial-only claim-binding candidates	26
Strict high-confidence sources	26
Admitted final sources	48

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mechanism, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=27; claims=1346	no extracted directional signal in 18/27 sources	4 direct; 11 indirect; 1 protocol; 11 review	limited corpus depth in this outcome class
Muscle Function	n=5; claims=355	no extracted directional signal in 3/5 sources	2 indirect; 1 protocol; 2 review	limited corpus depth in this outcome class
Immune and Inflammation	n=4; claims=226	unclear signal in 1/4 sources	1 indirect; 3 review	limited corpus depth in this outcome class
Cardiometabolic	n=3; claims=344	unclear signal in 1/3 sources	1 direct; 1 indirect; 1 review	limited corpus depth in this outcome class
Frailty	n=2; claims=185	unclear signal in 1/2 sources	1 direct; 1 indirect	limited corpus depth in this outcome class
Safety and Comorbidity	n=2; claims=127	unclear signal in 1/2 sources	1 direct; 1 review	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=79	positive signal in 1/1 sources	1 direct	single-source slice; hypothesis-generating
Dosing and Pharmacokinetics	n=1; claims=93	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Longevity	n=1; claims=159	positive signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Mechanism	n=1; claims=56	unclear signal in 1/1 sources	1 mechanistic	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=15	no extracted directional signal in 1/1 sources	1 direct	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Results Summary

• Contextual Adjacent Evidence: n=27; claims=1346; no extracted directional signal in 18/27 sources | directness: 4 direct; 11 indirect; 11 review; 1 protocol; main limitation: directionally heterogeneous.
• Muscle Function: n=5; claims=355; no extracted directional signal in 3/5 sources | directness: 2 indirect; 2 review; 1 protocol; main limitation: no direct clinical anchor.
• Cardiometabolic: n=3; claims=344; mixed signal in 1/3 sources | directness: 1 direct; 1 indirect; 1 review; main limitation: directionally heterogeneous.
• Immune and Inflammation: n=3; claims=157; mixed signal in 1/3 sources | directness: 1 indirect; 2 review; main limitation: no direct clinical anchor.
• Frailty: n=2; claims=185; mixed signal in 1/2 sources | directness: 1 direct; 1 indirect; main limitation: directionally heterogeneous.
• Safety and Comorbidity: n=2; claims=127; benefit signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.

Cardiometabolic Outcomes

Three sources within the curated corpus examined omega-3-related cardiometabolic outcomes, spanning a large ancillary randomized trial, a recent systematic review with meta-analysis, and an indirect observational cohort.

Quantitative findings in this class are heterogeneous and route-dependent. The full study-by-endpoint p-value matrix is tabulated in the evidence synthesis.

Mechanistically, the clinical RCT evidence in Tobias 2025 tests whether omega-3 supplementation reduces incident type 2 diabetes in a generally well-nourished older cohort, while the mechanistic human studies consolidated in Basirat 2025 and the metabolomic/lipidomic work in Wang 2025 interrogate upstream lipid-handling pathways — triglyceride-rich lipoprotein clearance, lipoprotein subclass remodeling, and antioxidant response — that are biologically proximal to cardiometabolic risk.

Additional corpus sources included animal/preclinical evidence; within-corpus tensions in this outcome class center on the directness of inference rather than on head-to-head discordant findings.

Tobias 2025 is the only direct clinical RCT in the cardiometabolic class, whereas Basirat 2025 is a review-level synthesis and Wang 2025 is an indirect observational cohort; the brief flags this as an indirectness gap between Tobias 2025 and each of the other two, and the two should be reported as separate lines of evidence rather than pooled.

Because the curation deliberately funnels non-longevity outcomes into a single contextual bucket, the human evidence base spans RCTs, observational cohorts, mechanistic studies, and review-level syntheses rather than a single causal pathway.

Quantitative signals within contextual other split sharply by direction.

Another tension concerns cardiometabolic outcomes, where the dose-response surface of omega-3 appears steep and clinically meaningful for triglycerides but shallow for hard cardiovascular endpoints. The boundary condition is baseline cardiovascular risk and baseline omega-3 status: populations with the highest absolute event rates (hemodialysis, hypertriglyceridemia, post-MI secondary prevention) capture the largest absolute risk reductions, while lower-risk primary-prevention cohorts (e. For example, DO-HEALTH older adults, Tobias 2025) show smaller or null effects. Resolution requires trials enrolling omega-3-deficient or high-risk cohorts with hard MACE endpoints and Omega-3 Index stratification.

Population / prevalence Outcomes

A single curated human trial directly addresses omega-3 polyunsaturated fatty acid (PUFA) status and its downstream biomarker consequences over a defined supplementation window. In a randomized double-blind design, 24 physically active young men were allocated to a 21-day omega-3 PUFA supplementation arm or comparator, with secretory factors and inflammation status as the mechanistic/biomarker endpoints (Konert 2026). The trial's compact 21-day duration and small n=24 sample frame it as a short-term mechanistic probe. Endpoint reporting centred on circulating inflammatory mediators and exercise-induced secretory factor kinetics rather than on hard longevity events.

The reported effect direction was positive, with statistically detectable changes in the targeted exercise-induced secretory factors and inflammation status markers at P < 0.01 and P < 0.05 (Konert 2026). These p-values are reproduced verbatim from the trial report and were not recomputed or rounded. Because the outcome class is deficiency prevalence, the relevant quantitative reading is whether supplementation shifted the biomarker profile in a direction consistent with restored or preserved status, and the trial reports such a shift. No confidence interval, hazard ratio, or between-group percentage was reported in the available excerpt, so quantitative interpretation is restricted to the reported significance levels.

Mechanistically, the findings align with the broader omega-3 longevity substrate in which eicosapentaenoic acid and docosahexaenoic acid intake modifies phospholipid membrane composition, eicosanoid balance, and the resolution-phase mediators that govern post-exercise secretory output (Konert 2026). Within the curated evidence base, this RCT sits alongside the mechanistic human studies and preclinical data streams that, Across the corpus, motivate the deficiency prevalence outcome class. The mechanistic substrate underlying this functional finding is the well-characterised shift from arachidonic-acid-derived series-2/4 eicosanoids toward series-3 counterparts, which is consistent with the inflammation-status endpoint change reported.

Within the corpus, no non-orthogonal tension pair is registered for the deficiency prevalence outcome class, so the only available signal is the Konert 2026 RCT itself. The corpus therefore does not yet provide a second direct human trial to corroborate or contest the magnitude of the reported status shift, and the boundary conditions — dose, baseline EPA/DHA, habitual fish intake, age band, and training load — remain to be established. The available evidence supports a positive direction of effect on deficiency-related biomarkers at the conventional P < 0.01 and P < 0.05 thresholds, while leaving the size of any population-level deficiency-reversal effect as a quantitative open question for the broader synthesis.

Dosing and Pharmacokinetics Outcomes

The meta-analysis therefore supports a linear dose-response slope while leaving the average effect size uncertain, a pattern relevant to the boundary conditions of omega-3 supplementation in older adults.

The P < 0.0001 slope versus the P = 0.09 overall effect illustrates that dose magnitude, not mere enrollment in an omega-3 trial, is the more reliable predictor of outcome direction. For the present synthesis, this implies that dose heterogeneity across the corpus must be treated as a first-class covariate when interpreting any downstream longevity signal, and that null findings from low-dose arms should not be aggregated with high-dose arms without explicit dose stratification.

By contrast, the non-significant overall pooled estimate (P = 0.09) reflects the well-known dilution effect when low-dose and high-dose arms are pooled without weighting for exposure. The within-corpus tension here is therefore not a disagreement between studies but a disagreement within a single meta-analysis between the dose-response coefficient and the average effect, which downstream outcome-specific subsections must respect when contextualizing their own null or positive findings.

Frailty Outcomes

Two studies in the curated corpus address the frailty outcome class, each taking a different approach to the older-adult population. Amini 2026 is a 5-armed randomized controlled feasibility trial enrolling community-dwelling older adults aged 65 years and over who were diagnosed with sarcopenia, and the intervention combines exercise, protein, and omega-3 supplementation within a multicomponent design. Eggimann 2024 is an observational cohort analysis embedded in the DO-HEALTH trial that examines change in appendicular lean mass index (ALMI) over 3 years using mixed effect models in the DXA sub-cohort (n = 1495). Together these two sources provide a direct-versus-indirect contrast on the same broad outcome domain, with the RCT testing the omega-3-containing package and the cohort study isolating supplementation effects on lean mass as a frailty-related surrogate.

The clinical RCT in Amini 2026 does not report a clear effect direction, reflecting the feasibility-stage nature of the trial in which sarcopenia outcomes were the primary endpoint but the design is not powered for a definitive efficacy claim.

Mechanistically, both studies target the same frailty-relevant substrate of age-related lean mass decline, but they operationalize it differently. Eggimann 2024 isolates supplementation in an observational cohort analysis, removing the exercise arm but retaining the indirect, surrogate-endpoint framing of lean mass rather than incident frailty. The mechanistic substrate underlying this functional finding is therefore the same anti-inflammatory and anabolic rationale, but the human-RCT evidence directly testing omega-3 in sarcopenia or frailty is sparse within the corpus.

The within-corpus tension between Amini 2026 and Eggimann 2024 is a direct-versus-indirect disagreement on the frailty outcome class, flagged in the cross-study disagreement map with severity 3. Amini 2026 measures the frailty-class outcome directly through sarcopenia diagnosis in a randomized population, whereas Eggimann 2024 measures it indirectly through DXA-derived ALMI change in an observational sub-cohort analysis. The corpus does not contain a third frailty-class source that could adjudicate this direct/indirect gap, so the boundary conditions under which omega-3 supplementation benefits frailty-class outcomes remain unresolved within the current evidence base.

A second load-bearing tension sits within the muscle function class itself, where the systematic review evidence is internally inconsistent. The likely mechanism for disagreement is population and stimulus specificity: anabolic synergy with resistance loading or amino acid availability is detectable in shorter protein-turnover studies, whereas free-living physical-activity change in already-active older adults and trained athletes is constrained by ceiling effects and behavioral adaptation. The boundary condition is therefore whether the comparator population is in a catabolic or anabolic deficit at baseline — frail and sarcopenic participants (Amini 2026; Eggimann 2024 in DO-HEALTH) plausibly have more room to respond than habitually active older adults. Resolution would require adequately powered RCTs stratified by baseline frailty status, with concurrent resistance training, and using accepted sarcopenia cutoffs (Cruz-Jentoft 2019: 27 kg grip strength for men, 16 kg for women) as continuous endpoints rather than binary incidence.

Immune and Inflammation Outcomes

Three curated references address immune and inflammatory endpoints under omega-3 exposure, with each contributing a distinct evidentiary design. Together, these three sources bracket the immune outcome class with review-level evidence on two disease populations and direct supplementation data on healthy adults.

The quantitative findings within this outcome class are heterogeneous and are catalogued in detail in the evidence synthesis.

Mechanistically, the immune-outcome findings map onto resolution of inflammation via specialized pro-resolving mediators, modulation of CRP and downstream acute-phase reactants, and tissue-specific protection in vascular and retinal beds. The mechanistic substrate underlying these functional findings — namely, EPA/DHA-driven shifts in membrane lipidomics and downstream prostaglandin/leukotriene profiles — is shared across the three sources even though their clinical contexts differ.

Okut 2025, in healthy adults receiving 3150 mg/day combined with strength training, shows favorable inflammatory and antioxidant responses, whereas Blair 2026, pooling haemodialysis trials, reports mixed pooled effects including P = 0.04 for CRP reduction and a negative overall direction. By contrast, Chen 2025 occupies an intermediate position in a metabolic-vascular disease population, with protection against sight-threatening DR (HR = 0.52) but a mixed p-value distribution including both P = 0.014 and P = 0.838 across endpoints. The analytic corpus spanned multiple contributing studies, with reproduced pooled analyses including total cholesterol (n = 15 contributing trials), HDL-C (n = 13), and triglycerides, alongside inflammatory markers. Effect direction across the reproduced analyses was coded as unclear in the curated evidence base, reflecting heterogeneity across the pooled endpoints rather than a uniformly negative or positive signal.

Quantitative findings from the reproduced pooled analyses include a statistically significant omnibus test of P < 0.001 for at least one of the lipid or inflammatory endpoints, alongside two non-significant comparisons reported as P = 0.275 and P = 0.133. Because the pooled sample sizes for HDL-C (n = 13) and the lipid panel (n = 15) differ, the non-significant p-values cannot be interpreted as evidence of equivalence without consulting the underlying effect sizes and confidence intervals, which are not reproduced in the curated excerpt.

Mechanistically, the inflammatory rationale for omega-3 in HIV rests on resolution of chronic innate immune activation via specialized pro-resolving mediators and on triglyceride-lowering via peroxisome proliferator-activated receptor pathways. Preclinical and mechanistic human studies have established that long-chain n-3 polyunsaturated fatty acids shift eicosanoid balance toward less inflammatory series-3 prostaglandins and series-5 leukotrienes, which is biologically consistent with the dyslipidaemia and immune-activation phenotype of treated HIV. The Bai 2026 meta-analysis sits at the translational interface between this mechanistic substrate and clinical RCT endpoints, with the mixed p-value profile reflecting the heterogeneity one would expect when pooling heterogeneous inflammatory markers across heterogeneous trial designs.

Within-corpus tensions for the immune outcome class are not formally declared in the cross-study disagreement map, which contains no same-outcome non-orthogonal pairs; however, the mixed p-value profile of P < 0.001 alongside P = 0.275 and P = 0.133 within a single meta-analytic source implies endpoint-level disagreement. The discordance between the strongly significant omnibus pooled estimate and the two non-significant secondary comparisons can be interpreted as a feature of the curated evidence base rather than as a rejection of any single source. The analysis was cross-sectional at baseline with prospective mortality follow-up, and the exposure was quantified as dietary n-3 PUFA intake in mg/kg per day, allowing dose-response modeling at the individual level. Mortality was treated as a discrete prospective endpoint layered on top of a graded CKM stage phenotype. Because the design is observational rather than interventional, the trial is classified as indirect with respect to a causal longevity claim, but it provides one of the more granular per-unit-intake estimates in the curated corpus., with reported P-values of P < 0.001, P = 0.014, P = 0.011, P = 0.015, P = 0.008, P = 0.024, and P = 0.02 across the principal analyses, and additional threshold-level findings at P = 0.047 and P < 0.05. The single non-significant contrast in the panel was P = 0.285, with a borderline value of P = 0.056 also reported. Across the corpus, the preponderance of source-traced P-values falls below conventional significance thresholds, and the effect direction is uniformly positive, supporting a monotonic inverse association between omega-3 intake and adverse CKM-mortality outcomes within this cohort., so a per-10 mg/kg per day shift in n-3 PUFA intake moving participants across CKM stages offers a clinically interpretable vector for the longevity signal. The mechanistic substrate underlying this functional finding, anti-inflammatory lipid mediator shifts and improved lipid particle handling, has been documented in adjacent human metabolic studies, although those studies do not enter the present corpus and therefore cannot be cited as in-corpus evidence.

Mechanistically, the within-source pattern of mixed p-values implies that the omega-3 substrate engages certain pathways more robustly than others, with at least one pathway returning a clearly null signal. In human-readable terms, the preclinical data suggest selective, rather than blanket, engagement of longevity-relevant biology. This selective engagement is the mechanistic backbone against which any human RCT longevity signal would need to be interpreted, and it cautions against assuming a single uniform mechanism underlies all downstream effects.

Muscle Function Outcomes

Five curated studies populate the muscle function outcome class, spanning an elite-athlete synbiotic trial, a meta-analysis of protein-synthesis endpoints, a network meta-analysis in trained athletes, a 3-year RCT ancillary analysis in active older adults, and a multicentre sarcopenia-prevention protocol.

Hussein 2025, leveraging the 3-year DO-HEALTH trial in generally healthy and active older adults testing vitamin D3, omega-3 fatty acids, and a simple home exercise program, reported a mixed significance pattern that did not uniformly favour the omega-3 arm (P = 0.01, P = 0.02, P = 0.004, P = 0.03, P = 0.32, P = 0.45, P = 0.14, P = 0.29, P = 0.26, P = 0.22, P = 0.33, P = 0.44, P = 0.51, with non-significant contrasts at P = 0.66 and P = 0.99). The detailed study-by-endpoint p-value matrix is presented in the evidence synthesis.

Mechanistically, the divergence across these muscle-function studies maps onto substrate plausibility rather than onto a single agreed pathway.

Within-corpus tensions on muscle function are concentrated in three null-versus-positive pairings, all of which pair the Therdyothin 2024 positive meta-analytic signal against an individual study reporting a null. First, Therdyothin 2024 versus Hussein 2025 yields a partial conflict: the meta-analysis aggregates protein-synthesis endpoints favouring omega-3, whereas the DO-HEALTH ancillary analysis in active older adults does not show uniformly positive physical-activity responses (with multiple non-significant contrasts including P = 0.32, P = 0.45, P = 0.66, and P = 0.99 alongside significant P = 0.01, P = 0.02, P = 0.004, and P = 0.03). The Zhang 2026b protocol does not arbitrate these tensions, as no p-values are reported, but it indicates that a dedicated, adequately powered RCT in older adults at high risk of sarcopenia is in progress and may resolve the boundary conditions under which omega-3's mechanistic plausibility translates into measurable functional gain.

Safety and Comorbidity Outcomes

Within the curated evidence corpus, the principal safety/comorbidity evidence comprises one human RCT protocol in older adults and one quantitative synthesis.

The two sources contribute non-overlapping evidence types to the safety/comorbidity outcome class. McDaniel 2020 is a direct human RCT in an enrolled clinical population of older adults with a defined wound-healing endpoint and pre-specified protocol parameters, but does not yet report a completed p-value (McDaniel 2020). the evidence synthesis records each per-study endpoint value as catalogued in the underlying source.

Mechanistically, the chronic-pain signal reported by Xie 2025 is consistent with corpus-level pathways linking omega-3 fatty acids to eicosanoid and specialised pro-resolving mediator biology, which provides a substrate for reduced inflammatory pain signalling. The McDaniel 2020 RCT in older adults with CVLUs targets a related but distinct pathway — chronic wound inflammation and tissue repair — and is therefore complementary rather than duplicative, as its primary endpoint is ulcer healing rather than pain intensity. By contrast, the McDaniel 2020 design is direct for the older-adult comorbidity population, while Xie 2025 sits at the review level and inherits the directness constraints of the trials it pools, which include both chronic-pain and mixed-age populations. Together, the two sources form a human clinical RCT (McDaniel 2020) plus a meta-analytic synthesis (Xie 2025) pairing that spans direct and review-level evidence on the safety/comorbidity axis.

A within-corpus tension is present between McDaniel 2020 and Xie 2025 on the safety/comorbidity outcome class. The study was positioned as a direct mechanistic/biomarker investigation of fracture incidence, with the factorial design allowing isolation of the omega-3 component from co-interventions.

Within the curated corpus, no p-values were reported for the omega-3 versus fracture comparison (p values: []), and the effect direction is logged as null. Rather than fabricate quantitative outputs, the synthesis acknowledges that the available source indicates a null or non-significant contribution of omega-3 supplementation to incident vertebral fracture reduction in the DO-HEALTH population. the evidence synthesis (Per-Study Endpoint Evidence) carries the precise per-arm numerics as supplied by the source, and readers are directed there for endpoint-by-endpoint breakdown.

Mechanistically, omega-3 polyunsaturated fatty acids have been linked in preclinical and human biomarker work to modulation of inflammatory cytokines and to osteoblast/osteoclast balance, which provides a plausible substrate for skeletal effects. This tension between mechanistic plausibility and a clinical RCT null result is exactly the kind of boundary-condition finding the synthesis flags for further stratification.

Within the corpus, the DO-HEALTH source is the sole direct skeletal-fracture evidence stream, so no within-outcome disagreement can be triangulated here. The synthesis therefore treats this subsection as evidence that, for vertebral fracture incidence over 3 years of supplementation, omega-3 alone does not produce a detectable reduction in the DO-HEALTH cohort — a negative-for-benefit finding that tempers mechanistic optimism. The boundary condition appears to be exposure: mechanistic and biomarker endpoints typically require days to weeks of supplementation and detect acute pathway modulation, whereas longevity, sarcopenia, and incident type 2 diabetes endpoints require years and adequate statistical power.

Another tension that the corpus sharpens is that aging-relevant outcomes split along a frail-versus-robust axis in ways that single-outcome syntheses obscure. The boundary condition is therefore baseline tissue status, not the agent itself.

A fifth, more interpretive tension is the asymmetric evidentiary weight between cancer and surgical recovery literatures (where omega-3 appears consistently beneficial) and the broader healthspan, cognitive, and pain literatures (where it does not). The mechanism-level reconciliation is that acute catabolic stress creates a clear, time-limited substrate window in which anti-inflammatory and anabolic actions of omega-3 can be detected, whereas chronic low-grade states (mild cognitive impairment, fibromyalgia-type pain, slow visual decline) have multiple drivers and high between-study heterogeneity.

The boundary condition is therefore the reversibility of the underlying deficit: when there is an acute inflammatory or catabolic insult, the signal is detectable; when the deficit is chronic, multifactorial, or mild, the signal attenuates and may be lost in noise. Resolution would require head-to-head trials in the same population measuring both acute surgical and chronic healthspan endpoints, with pre-specified Omega-3 Index thresholds and pre-registered dose, so the boundary can be empirically located rather than inferred from across-study comparisons.

Contextual Adjacent Evidence Outcomes

Additional corpus sources included animal/preclinical evidence; the trial-design spread is therefore unusually wide, with source-level directness ranging from direct mechanistic RCTs (Beauregard 2025, Reyes-Perez 2025, Park 2025, Madurasinghe 2026) to review-level indirectness (Rittenhouse 2025, Delsoglio 2025, Li 2026, Saadh 2025, Alzahrani 2025, Gong 2025, Shokravi 2026, Anthony 2026).

Mechanistically, the within-class pattern reflects three overlapping substrates. First, marine ω-3 PUFAs appear to shift membrane-phospholipid and resolvin-pathway mediators that are directly measurable in blood and tissue, which explains why RCT-grade mechanistic biomarkers in Madurasinghe 2026, Reyes-Perez 2025, Anthony 2026, and Park 2025 cluster on the positive side of the distribution. Second, several aging-relevant endpoints — most notably the DO-HEALTH methylation-clock analysis (Bischoff-Ferrari 2025), the PREDIMED-Plus atrial-fibrillation biomarker trajectories (Moreno 2026), the HS-Omega-3 Index complication analysis (Mueller 2025), and the glaucoma/IOP evaluations (Pan 2026, Luo 2025) — yield predominantly null or near-null signals, suggesting that biomarker tractability does not automatically translate into aging-clock or hard-outcome movement.

Additional corpus sources included animal/preclinical evidence; within-corpus tensions in this outcome class are dense and structural rather than incidental. The clearest partial conflict pits the broadly positive review-level signal in Gong 2025 against the null findings in Bischoff-Ferrari 2025, Liu 2025, Li 2025b, Cardona 2025, MateuArrom 2025, Luo 2025, Maymandinejad 2025, Li 2025, Barros 2025, Enriquez 2025, Mueller 2025, Chou 2026, Shokravi 2026, Pan 2026, and Moreno 2026, while Delsoglio 2025 supplies an independent positive counterpoint that aligns with Gong 2025 on the direction of effect. Another tension layer is directness: the four direct RCTs (Beauregard 2025, Reyes-Perez 2025, Park 2025, Madurasinghe 2026) cannot be averaged with the broader review and indirect cohort literature because they answer different evidentiary questions — mechanism versus population-level outcome translation — and Rittenhouse 2025 in particular is a review of military performance/recovery that should not be conflated with the ASCEND-style adherence RCT in Madurasinghe 2026 or the DHA/EPA neuroprotection protocol in Beauregard 2025. A third, more granular disagreement is the within-RCT split between Madurasinghe 2026 (positive on adherence/biomarker coupling) and Park 2025 (null on the broader pain-interference construct) and between Madurasinghe 2026 and Reyes-Perez 2025, reflecting how the same molecular substrate can yield divergent readouts depending on whether the endpoint is adherence, inflammatory marker flux, or symptom interference. Across the corpus, these disagreements justify a context-dependent reading: marine ω-3 effects on mechanistic biomarkers are reproducible, while their translation into aging-clock movement, surgical recovery, ocular endpoints, and dialysis cardiovascular events remains unsettled and warrants outcome-specific rather than umbrella-level interpretation.

Contextual Adjacent Evidence remains a separate Results slice (n=27; claims=1346; no extracted directional signal in 18/27 sources; 4 direct; 11 indirect; 1 protocol; 11 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Longevity Outcomes

Within-corpus tensions for the longevity class are limited because only one source (Zhang 2026) populates this outcome class, and the cross-study disagreement map contains no same-outcome non-orthogonal pairs to adjudicate., indicating a mixture of strong positive signals and at least one null result. This pattern of effect heterogeneity is consistent with a context-dependent mechanistic profile rather than a uniformly active substrate.

Longevity remains a separate Results slice (n=1; claims=159; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Mechanism Outcomes

Within the available corpus, the Schlogelhofer 2025 mechanistic record stands alone for this outcome class, which limits within-corpus tensions; no same-outcome non-orthogonal pair is present in the cross-study disagreement map. The direction of the dominant effect in this preclinical study is reported as unclear, which means the mechanistic case for longevity benefit rests on the strength of the p-values rather than on a uniformly favorable effect direction.

Skeletal, Fracture, and Bone Outcomes

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

Cross-Domain Synthesis

Cross-domain interpretation of Omega 3 longevity is constrained by the relationship between clinical sources (Amini 2026, Tobias 2025, Konert 2026) and mechanistic studies (Schlogelhofer 2025). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in the contextual adjacent evidence, longevity, safety and comorbidity outcome classes with null signals in the contextual adjacent evidence, muscle function and cardiometabolic outcome classes and negative signals in the immune and inflammation outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

389 non-orthogonal tensions prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

Discussion

Thesis: Across 48 curated reference papers, the evidence base for Omega 3 shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: immune. Null findings dominate: muscle function. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 48 included sources. The evidence-tier distribution is: B2 (n=23), B1 (n=13), A1 (n=9), D1 (n=2), C1 (n=1). By directness, the breakdown is: review (n=19), indirect (n=17), direct (n=9), protocol (n=2), mechanistic (n=1). 34 of 48 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; older adults; adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus is missing the trial class most directly relevant to a longevity claim. No large, long-duration randomized controlled trial in non-diabetic, community-dwelling adults with omega-3 supplementation as the primary exposure and all-cause mortality as the prespecified primary endpoint is represented in the curated evidence. As a consequence, the present synthesis cannot state, and does not state, that omega-3 supplementation extends life expectancy; any longevity framing rests on inference from surrogate or proximate outcomes and from observational association. This is the central corpus-level limitation and the one that most directly bounds the conclusions in the abstract.

Additional corpus sources included animal/preclinical evidence; several outcomes in the evidence base are touched by only a single source, which means replication within the corpus is impossible. Muscle protein synthesis is supported exclusively by the Therdyothin 2024 systematic review, with no independent primary trial on the same anabolic endpoint in the curated set. Sarcopenia incidence as a longitudinal clinical endpoint rests on Amini 2026 (a 5-armed feasibility RCT in community-dwelling adults ≥65 years) without an independent confirmatory trial of comparable duration. Biological aging as operationalized by DNA methylation clocks is captured by Bischoff-Ferrari 2025 alone, and incident vertebral fracture reduction is captured by Kistler-Fischbacher 2025 alone. Single-study evidence is also the entire basis for several contextual claims, including the olfactory benefit in Alzahrani 2025, the glaucoma risk reduction in Pan 2026, the uremic-pruritus dose-response in Chou 2026, and the topical skin applications catalogued in MateuArrom 2025. Because the corpus contains no independent corroborating evidence for any of these single-source outcomes, the synthesis must treat each as provisional: the absence of a second source is not a vote of confidence, it is a structural gap, and any pooled claim that aggregates across these singletons would overstate the available evidence. The Limitations section therefore reads these findings as hypothesis-generating rather than confirmatory.

Several endpoints that a reader would expect in an anti-aging synthesis are not measured at all in the curated corpus. Healthspan — defined as the period of life spent in good health, distinct from lifespan — has no direct endpoint coverage; the closest surrogates are grip strength and sarcopenia (Amini 2026, Hussein 2025, Eggimann 2024; sarcopenia cutoffs for men and women, Cruz-Jentoft 2019, are 27 kg and 16 kg respectively), gait speed (canonical frailty thresholds of 0.8 m/s, Studenski 2011, and 0.6 m/s, Cesari 2009, with substantial change of 0.1 m/s, Perera 2006, and annual age-related decline of 0.05 m/s, Bohannon 1997), and DNA methylation clocks (Bischoff-Ferrari 2025). Functional status, ADL preservation, and disability-free survival are not directly reported. Hospitalization, length of stay, and surgical recovery are addressed by Delsoglio 2025 and Li 2026, but these are not aging outcomes in the conventional sense. Mortality is touched by Zhang 2026 (observational), and an HbA1c-style metabolic endpoint is captured by Tobias 2025 (ADA 2024 target 7% for most adults with diabetes; 6.5% for younger / lower-risk patients), but the link from metabolic improvement to survival benefit is itself an inferential step, not a measurement. The absence of healthspan as a measured variable is a substantive limitation, not merely a stylistic one.

The mechanism-to-clinic gap is unusually wide in this evidence base. The mechanistic literature is substantial and internally consistent — omega-3 modulates inflammation, lipid mediators, cell-membrane fluidity, and multiple downstream signaling pathways — but the clinical literature on the same biology is heterogeneous. A worked example is muscle protein synthesis: Therdyothin 2024 reports a positive mechanistic / kinetic effect, while three independent human trials (Hussein 2025, Imanian 2025, Wang 2026) report null effects on functional muscle endpoints, and Kistler-Fischbacher 2025 reports no reduction in incident vertebral fractures over 3 years of supplementation. The mechanism therefore exists; the clinical translation does not, in this corpus. Methodologically, the cautionary principle articulated by Ioannidis 2005 — that surrogate associations do not guarantee hard-outcome validity — applies throughout: where the corpus has only mechanistic evidence for a clinically relevant claim (longevity, healthspan, disability-free survival), the synthesis explicitly declines to promote that claim. This boundary is the principal reason the headline conclusion remains incomplete.

Conclusion

For Omega 3 longevity, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 48 included sources on Omega 3 Longevity across 12 outcome classes and 389 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 48 curated reference papers, the evidence base for Omega 3 shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Negative signals appear in: immune. Null findings dominate: muscle function. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the disagreement between Okut 2025 and Blair 2026 on immune and inflammation (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Rittenhouse 2025, Basirat 2025, Chen 2025, Xie 2025, Shahinfar 2025) emphasize convergent signals on Omega 3 Longevity. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	positive	direct interventional hard-endpoint gap
muscle function	0	5	null, positive, unclear	conflict-resolution gap
immune and inflammation	0	3	mixed, negative, positive	conflict-resolution gap
mechanism	0	1	unclear	direct interventional hard-endpoint gap
cardiometabolic	1	2	mixed, null, unclear	replication gap
frailty	1	1	null, unclear	replication gap
dosing and pharmacokinetics	0	1	unclear	direct interventional hard-endpoint gap
immune and inflammation	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	4	23	mixed, null, positive, unclear	conflict-resolution gap
deficiency prevalence	1	0	positive	replication gap
safety and comorbidity	1	1	positive, unclear	replication gap
skeletal, fracture, and bone	1	0	null	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: positive
P2	muscle function: conflict-resolution gap	0 direct and 5 indirect sources; direction profile: null, positive, unclear
P3	immune and inflammation: conflict-resolution gap	0 direct and 3 indirect sources; direction profile: mixed, negative, positive
P4	mechanism: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P5	cardiometabolic: replication gap	1 direct and 2 indirect sources; direction profile: mixed, null, unclear

Next-Study Design Recommendation

The next high-yield study for Omega 3 Longevity should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Amini 2026; tier=A1; directness=direct; endpoint=frailty; direction=unclear.
• Tobias 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.035.
• Konert 2026; tier=A1; directness=direct; endpoint=deficiency prevalence; direction=positive; representative statistic=P < 0.01.
• Madurasinghe 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.0001.
• Park 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.057.
• Beauregard 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
• Reyes-Perez 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
• McDaniel 2020; tier=A1; directness=direct; endpoint=safety comorbidity; direction=unclear.
• Kistler-Fischbacher 2025; tier=A1; directness=direct; endpoint=skeletal fracture bone; direction=null.
• Rittenhouse 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial: outcome=frailty; directness=direct; tier=A1; direction=unclear; claims=143.
• Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=140.
• Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial: outcome=deficiency prevalence; directness=direct; tier=A1; direction=positive; claims=79.
• Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=77.
• Associations Between Dietary Intakes of Omega-3 Fatty Acids, Blood Levels, and Pain Interference in People with Migraine: A Path Analysis of Randomized Trial Data: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=33.
• Investigating omega-3 fatty acids’ neuroprotective effects in repetitive subconcussive neural injury: Study protocol for a randomized placebo-controlled trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=22.
• Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO): outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=22.
• Impact of omega-3 fatty acid oral therapy on healing of chronic venous leg ulcers in older adults: Study protocol for a randomized controlled single-center trial: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=21.
• Effects of vitamin D3, omega-3s, and a simple home exercise program on incident vertebral fractures: the DO-HEALTH randomized controlled trial: outcome=skeletal fracture bone; directness=direct; tier=A1; direction=null; claims=15.
• Examining the Influence of Omega-3 Fatty Acids on Performance, Recovery, and Injury Management for Health Optimization: A Systematic Review Focused on Military Service Members: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=149.
• Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=127.
• Association between omega-3 fatty acid intake and risk of diabetic retinopathy: A systematic review and meta-analysis: outcome=immune; directness=review; tier=B1; direction=mixed; claims=117.
• Effects of omega-3 fatty acids on chronic pain: a systematic review and meta-analysis: outcome=safety comorbidity; directness=review; tier=B1; direction=positive; claims=106.
• A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function: outcome=dosing pharmacokinetics; directness=review; tier=B1; direction=unclear; claims=93.
• The effects of omega-3 polyunsaturated fatty acids on muscle and whole-body protein synthesis: a systematic review and meta-analysis: outcome=muscle function; directness=review; tier=B1; direction=positive; claims=86.
• Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis: outcome=immune inflammation; directness=review; tier=B1; direction=unclear; claims=69.
• The effect of omega-3 supplementation on metabolic, inflammatory and oxidative stress biomarkers in pregnant women: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=56.
• Efficacy of Omega-3 supplementation in olfactory dysfunction: a systematic review of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=48.
• Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=46.
• Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=null; claims=35.
• Impact of Omega-3 Polyunsaturated Fatty Acids on Alcohol Use and Negative Consequences: A Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=null; claims=27.
• Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis.: outcome=immune; directness=review; tier=B1; direction=negative; claims=11.
• Association of Higher Dietary Omega‐3 Fatty Acid Intake With Cardiovascular‐Kidney‐Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross‐Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=159.
• Microencapsulated docosahexaenoic acid increases the Omega-3 Index and attenuates the physiological impact of eccentric exercise in physically trained adults: a 12-week double-blind placebo-controlled trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=151.
• High-protein oral nutritional supplement use in patients with cancer reduces complications and length of hospital stay: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=124.
• Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut–Muscle Axis Modulation During Race-Pace Training: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=123.
• The Role of Omega-3 Polyunsaturated Fatty Acid Supplementation in Postoperative Recovery of Colorectal Cancer: Systematic Review and Meta-Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=78.
• Comparative Effects of Dietary Protein, Creatine, and Omega-3 Supplementation on Muscle Strength, Endurance, and Recovery in Trained Athletes: A Systematic Review and Network Meta-Analysis: outcome=muscle function; directness=review; tier=B2; direction=null; claims=78.
• Effects of Omega-3 PUFAs on lipid profiles and antioxidant response in depressed adolescents: A metabolomic and lipidomic study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=77.
• Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=75.
• Potential ocular health benefit of short-term omega-3 fatty acids supplementation on the ocular tear film: An observational study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=71.
• Low HS-Omega-3 index as a predictor of severe postoperative complications in abdominal surgery: a prospective observational study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=64.
• Preliminary evaluation on the effect of oral omega-3 supplementation from herring caviar oil in primary open-angle glaucoma patients: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=61.
• Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=52.
• Effect of vitamin D, omega‐3 supplementation, or a home exercise program on muscle mass and sarcopenia: DO‐HEALTH trial: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=42.
• Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=41.
• The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults: outcome=immune; directness=indirect; tier=B2; direction=positive; claims=29.
• Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=27.
• Therapeutic Benefits of Topical Omega‐3 Polyunsaturated Fatty Acids in Skin Diseases and Cosmetics: An Updated Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=27.
• Genetic evidence reveals phosphatidylcholine as a mediator in the causal relationship between omega-3 and multiple myeloma risk: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=18.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Okut 2025 vs Blair 2026; Okut 2025 reports positive effect on immune; Blair 2026 reports negative on the same outcome — direct conflict
• Severity 4 null vs positive: Therdyothin 2024 vs Hussein 2025; Therdyothin 2024 (positive on muscle function) vs Hussein 2025 (null on muscle function) — partial conflict
• Severity 4 null vs positive: Therdyothin 2024 vs Imanian 2025; Therdyothin 2024 (positive on muscle function) vs Imanian 2025 (null on muscle function) — partial conflict
• Severity 4 null vs positive: Therdyothin 2024 vs Wang 2026; Therdyothin 2024 (positive on muscle function) vs Wang 2026 (null on muscle function) — partial conflict
• Severity 4 null vs positive: Bischoff-Ferrari 2025 vs Gong 2025; Gong 2025 (positive on contextual other) vs Bischoff-Ferrari 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Bischoff-Ferrari 2025 vs Delsoglio 2025; Delsoglio 2025 (positive on contextual other) vs Bischoff-Ferrari 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Gong 2025 vs Liu 2025; Gong 2025 (positive on contextual other) vs Liu 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Gong 2025 vs Li 2025b; Gong 2025 (positive on contextual other) vs Li 2025b (null on contextual other) — partial conflict

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Almutairi 2026.

References

• Zhang 2026. Association of Higher Dietary Omega‐3 Fatty Acid Intake With Cardiovascular‐Kidney‐Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross‐Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2026. DOI: 10.1161/JAHA.125.046079. PMID: 41532525.
• Anthony 2026. Microencapsulated docosahexaenoic acid increases the Omega-3 Index and attenuates the physiological impact of eccentric exercise in physically trained adults: a 12-week double-blind placebo-controlled trial. European Journal of Nutrition, 2026. DOI: 10.1007/s00394-026-03998-6. PMID: 42213158.
• Rittenhouse 2025. Examining the Influence of Omega-3 Fatty Acids on Performance, Recovery, and Injury Management for Health Optimization: A Systematic Review Focused on Military Service Members. Nutrients, 2025. DOI: 10.3390/nu17020307. PMID: 39861437.
• Amini 2026. A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial. The Journal of Frailty & Aging, 2026. DOI: 10.1016/j.tjfa.2025.100129. PMID: 41632571.
• Tobias 2025. Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. Nature Communications, 2025. DOI: 10.1038/s41467-025-58721-6. PMID: 40199888.
• Basirat 2025. Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2025. DOI: 10.3390/nu17203279. PMID: 41156531.
• Delsoglio 2025. High-protein oral nutritional supplement use in patients with cancer reduces complications and length of hospital stay: a systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1654637. PMID: 41001134.
• Imanian 2025. Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut–Muscle Axis Modulation During Race-Pace Training. Nutrients, 2025. DOI: 10.3390/nu17182959. PMID: 41010484.
• Chen 2025. Association between omega-3 fatty acid intake and risk of diabetic retinopathy: A systematic review and meta-analysis. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100632. PMID: 40987202.
• Xie 2025. Effects of omega-3 fatty acids on chronic pain: a systematic review and meta-analysis. Frontiers in Medicine, 2025. DOI: 10.3389/fmed.2025.1654661. PMID: 41267881.
• Shahinfar 2025. A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function. Scientific Reports, 2025. DOI: 10.1038/s41598-025-16129-8. PMID: 40836005.
• Therdyothin 2024. The effects of omega-3 polyunsaturated fatty acids on muscle and whole-body protein synthesis: a systematic review and meta-analysis. Nutrition Reviews, 2024. DOI: 10.1093/nutrit/nuae055. PMID: 38777807.
• Konert 2026. Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial. Nutrients, 2026. DOI: 10.3390/nu18030539. PMID: 41683362.
• Li 2026. The Role of Omega-3 Polyunsaturated Fatty Acid Supplementation in Postoperative Recovery of Colorectal Cancer: Systematic Review and Meta-Analysis. Nutrients, 2026. DOI: 10.3390/nu18010173.
• Wang 2026. Comparative Effects of Dietary Protein, Creatine, and Omega-3 Supplementation on Muscle Strength, Endurance, and Recovery in Trained Athletes: A Systematic Review and Network Meta-Analysis. Nutrients, 2026. DOI: 10.3390/nu18060909. PMID: 41901084.
• Wang 2025. Effects of Omega-3 PUFAs on lipid profiles and antioxidant response in depressed adolescents: A metabolomic and lipidomic study. Redox Biology, 2025. DOI: 10.1016/j.redox.2025.103617. PMID: 40158256.
• Madurasinghe 2026. Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes. Trials, 2026. DOI: 10.1186/s13063-026-09551-4. PMID: 41749263.
• Pan 2026. Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. Translational Vision Science & Technology, 2026. DOI: 10.1167/tvst.15.6.2. PMID: 42223316.
• Almutairi 2026. Potential ocular health benefit of short-term omega-3 fatty acids supplementation on the ocular tear film: An observational study. Medicine, 2026. DOI: 10.1097/MD.0000000000046566. PMID: 41367008.
• Bai 2026. Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1746723. PMID: 41883419.
• Mueller 2025. Low HS-Omega-3 index as a predictor of severe postoperative complications in abdominal surgery: a prospective observational study. International Journal of Surgery (London, England), 2025. DOI: 10.1097/JS9.0000000000003039. PMID: 40717591.
• Luo 2025. Preliminary evaluation on the effect of oral omega-3 supplementation from herring caviar oil in primary open-angle glaucoma patients. International Ophthalmology, 2025. DOI: 10.1007/s10792-025-03693-1. PMID: 40690043.
• Schlogelhofer 2025. Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study. The Australian and New Zealand Journal of Psychiatry, 2025. DOI: 10.1177/00048674251361758. PMID: 40855720.
• Saadh 2025. The effect of omega-3 supplementation on metabolic, inflammatory and oxidative stress biomarkers in pregnant women: a systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1639906. PMID: 41058996.
• Hussein 2025. Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100528. PMID: 40054416.
• Alzahrani 2025. Efficacy of Omega-3 supplementation in olfactory dysfunction: a systematic review of randomized controlled trials. BMC Nutrition, 2025. DOI: 10.1186/s40795-025-01114-1. PMID: 40624586.
• Gong 2025. Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis. Translational Psychiatry, 2025. DOI: 10.1038/s41398-025-03317-3. PMID: 40169548.
• Enriquez 2025. Study Protocol and Baseline Cardiometabolic Characterization of the RIO-Study (Response to an Intervention with Omega-3): A Randomized, Double-Blind, Placebo-Controlled Crossover Trial on Lipid and Inflammatory Profiles in Overweight and Obese Adults with Hypertriglyceridemia in Valdivia, Chile. Nutrients, 2025. DOI: 10.3390/nu17213397. PMID: 41228467.
• Eggimann 2024. Effect of vitamin D, omega‐3 supplementation, or a home exercise program on muscle mass and sarcopenia: DO‐HEALTH trial. Journal of the American Geriatrics Society, 2024. DOI: 10.1111/jgs.19266. PMID: 39565152.
• Maymandinejad 2025. Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance. Nutrients, 2025. DOI: 10.3390/nu17142296. PMID: 40732922.
• Shokravi 2026. Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis. Future Cardiology, 2026. DOI: 10.1080/14796678.2026.2645005. PMID: 41851014.
• Park 2025. Associations Between Dietary Intakes of Omega-3 Fatty Acids, Blood Levels, and Pain Interference in People with Migraine: A Path Analysis of Randomized Trial Data. Nutrients, 2025. DOI: 10.3390/nu18010003. PMID: 41515121.
• Okut 2025. The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults. Nutrients, 2025. DOI: 10.3390/nu17132088. PMID: 40647193.
• Bischoff-Ferrari 2025. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 2025. DOI: 10.1038/s43587-024-00793-y. PMID: 39900648.
• Cardona 2025. Impact of Omega-3 Polyunsaturated Fatty Acids on Alcohol Use and Negative Consequences: A Systematic Review. Nutrition Reviews, 2025. DOI: 10.1093/nutrit/nuaf036. PMID: 40139917.
• MateuArrom 2025. Therapeutic Benefits of Topical Omega‐3 Polyunsaturated Fatty Acids in Skin Diseases and Cosmetics: An Updated Systematic Review. Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.70341. PMID: 40616290.
• Beauregard 2025. Investigating omega-3 fatty acids’ neuroprotective effects in repetitive subconcussive neural injury: Study protocol for a randomized placebo-controlled trial. PLOS One, 2025. DOI: 10.1371/journal.pone.0321808. PMID: 40273177.
• Reyes-Perez 2025. Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO). Nutrients, 2025. DOI: 10.3390/nu17233630. PMID: 41373925.
• McDaniel 2020. Impact of omega-3 fatty acid oral therapy on healing of chronic venous leg ulcers in older adults: Study protocol for a randomized controlled single-center trial. Trials, 2020. DOI: 10.1186/s13063-019-3970-7. PMID: 31948466.
• Li 2025. Genetic evidence reveals phosphatidylcholine as a mediator in the causal relationship between omega-3 and multiple myeloma risk. Scientific Reports, 2025. DOI: 10.1038/s41598-025-12804-y. PMID: 40781111.
• Moreno 2026. Effect of Omega-3 Fatty Acid Intake on Circulating Biomarkers of Atrial Fibrillation-Related Pathways in the PREDIMED-Plus Study. Nutrients, 2026. DOI: 10.3390/nu18111669. PMID: 42280313.
• Zhang 2026b. Omega-3 polyunsaturated fatty acid supplementation for muscle health in community-dwelling older adults at high risk of sarcopenia: protocol for a multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-113455. PMID: 41760148.
• Kistler-Fischbacher 2025. Effects of vitamin D3, omega-3s, and a simple home exercise program on incident vertebral fractures: the DO-HEALTH randomized controlled trial. Journal of Bone and Mineral Research, 2025. DOI: 10.1093/jbmr/zjaf058. PMID: 40492704.
• Liu 2025. Effect of omega-3 polyunsaturated fatty acid on endometriosis. Clinics, 2025. DOI: 10.1016/j.clinsp.2025.100654. PMID: 40273491.
• Blair 2026. Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis. Clin Nutr ESPEN, 2026. DOI: 10.1016/j.clnesp.2026.102957. PMID: 41692069.
• Barros 2025. Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews. Nutrients, 2025. DOI: 10.3390/nu17183002. PMID: 41010527.
• Chou 2026. Effectiveness of Eicosapentaenoic and Docosahexaenoic Acid Supplementation for Reducing Uremic Pruritus: A Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals, 2026. DOI: 10.3390/ph19010181. PMID: 41599777.
• Li 2025b. Dietary Omega-3 PUFAs in Metabolic Disease Research: A Decade of Omics-Enabled Insights (2014–2024). Nutrients, 2025. DOI: 10.3390/nu17111836. PMID: 40507105.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.